

Site and Network Information

**NIH/NHLBI ACTIV-4 ACUTE:**

**COVID-19 Acute Inpatient Antithrombotic Study**

*Also called the Blood Thinner Study*



This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic strategies for prevention of adverse outcomes in patients hospitalized for COVID-19.

**We invite you to join as a site for a clinical trial that aims to identify the most appropriate strategy to prevent adverse outcomes in the COVID-19 inpatients. For more information or to join, contact us at: [ACTIV4ACUTE@nyulangone.org](mailto:ACTIV4ACUTE@nyulangone.org)**

**Intervention:** 2 Arms:

- i. prophylactic dose anticoagulation
- ii. therapeutic dose anticoagulation

**Inclusion/Exclusion Criteria:**

- Hospitalized for COVID-19+, age 18 or over
- Expected to require > 72 hours of hospitalization
- Patients with pregnancy or contraindication to anticoagulation are excluded

**Primary Outcome:** 21 Day Organ Support Free Days, which is defined as the number of days that a patient is alive and free of organ support through the first 21 days after trial entry. Organ Support is defined as receipt of invasive or non-invasive mechanical ventilation, high flow nasal oxygen, vasopressor therapy, or ECMO, with death at any time (including beyond 21 days) during hospitalization assigned -1 days.

**Key Secondary Outcome:** Composite of death, pulmonary embolism, systemic arterial thromboembolism, myocardial infarction, or ischemic stroke at hospital discharge or 28 days, whichever occurs first.

**Primary Safety Endpoint:** Major bleeding (as defined by the ISTH)

Secondary Safety Endpoints: Symptomatic intracranial hemorrhage, Confirmed heparin induced thrombocytopenia (HIT).

**Expected Enrollment Setting:** Inpatient non-ICU level of care and ICU

**Analysis Considerations:** 2000 patient target. Modified ITT including only participants who are confirmed to meet eligibility criteria. Adaptive component allows modification of study arms' continuation and duration, subject numbers and eligibility criteria based on safety and efficacy.

**Other Study Design Features:**

- Electronic tools will be available to facilitate consent.
- **Co-enrollment in other COVID-19 trials is permitted**
- These medications (heparins) and doses are approved for preventing and treating blood clots in different situations
- Biobanking blood (20ml) for studies of biomarkers of inflammation and coagulation will be an optional part of this trial.